| Literature DB >> 30429257 |
Roberto Alcántara1, Patricia Fuentes1, Ricardo Antiparra1, Marco Santos1, Robert H Gilman2, Daniela E Kirwan3, Mirko Zimic1, Patricia Sheen4.
Abstract
Although pyrazinamide (PZA) is a key component of first- and second-line tuberculosis treatment regimens, there is no gold standard to determine PZA resistance. Approximately 50% of multidrug-resistant tuberculosis (MDR-TB) and over 90% of extensively drug-resistant tuberculosis (XDR-TB) strains are also PZA resistant. pncA sequencing is the endorsed test to evaluate PZA susceptibility. However, molecular methods have limitations for their wide application. In this study, we standardized and evaluated a new method, MODS-Wayne, to determine PZA resistance. MODS-Wayne is based on the detection of pyrazinoic acid, the hydrolysis product of PZA, directly in the supernatant of sputum cultures by detecting a color change following the addition of 10% ferrous ammonium sulfate. Using a PZA concentration of 800 µg/ml, sensitivity and specificity were evaluated at three different periods of incubation (reading 1, reading 2, and reading 3) using a composite reference standard (MGIT-PZA, pncA sequencing, and the classic Wayne test). MODS-Wayne was able to detect PZA resistance, with a sensitivity and specificity of 92.7% and 99.3%, respectively, at reading 3. MODS-Wayne had an agreement of 93.8% and a kappa index of 0.79 compared to the classic Wayne test, an agreement of 95.3% and kappa index of 0.86 compared to MGIT-PZA, and an agreement of 96.9% and kappa index of 0.90 compared to pncA sequencing. In conclusion, MODS-Wayne is a simple, fast, accurate, and inexpensive approach to detect PZA resistance, making this an attractive assay especially for low-resource countries, where TB is a major public health problem.Entities:
Keywords: MODS; pyrazinamide; pyrazinoic acid; sputum; tuberculosis
Mesh:
Substances:
Year: 2019 PMID: 30429257 PMCID: PMC6355525 DOI: 10.1128/JCM.01162-18
Source DB: PubMed Journal: J Clin Microbiol ISSN: 0095-1137 Impact factor: 5.948
FIG 1MODS-Wayne plate design. Three samples were evaluated in each plate. One control well was included for every sample for each reading (R1, R2, and R3). Red arrows represent the 3 days of incubation after pyrazinamide (PZA) addition. Ferrous ammonium sulfate (SAF) was added after the incubation with PZA.
FIG 2MODS-Wayne results. The intensity of the color is enough to allow discrimination between a positive (presence of pink color) result (A), and a negative (absence of pink color) result (B), indicating pyrazinamide (PZA) susceptibility and resistance, respectively.
Description of patients from whom sputum samples were obtained
| Characteristic | No. (%) |
|---|---|
| Patients | |
| Callao reference lab | 162 (83.9) |
| Hospital Nacional Dos de Mayo | 31 (16.1) |
| Sex | |
| Female | 59 (30.1) |
| Male | 113 (58.6) |
| Data not available | 22 (11.4) |
| Age (yr) | |
| 13–22.3 | 33 (17.1) |
| 22.3–31.5 | 30 (15.5) |
| 31.5–40.8 | 27 (13.9) |
| 40.8–50 | 23 (11.9) |
| 50–59.3 | 19 (9.8) |
| 59.3–68.5 | 8 (4.1) |
| 68.5–77.8 | 6 (3.1) |
| 77.8–87 | 4 (2.1) |
| Data not available | 43 (22.3) |
| TB treatment | |
| Never treated | 93 (48.2) |
| Previous or ongoing treatment | 21 (10.9) |
| Data not available | 79 (40.9) |
All samples met the following criteria: minimum volume of 2 ml and positive acid-fast microscopy results (health center’s results).
Mutations in the putative promoter and pncA gene reported in this study
| Genotype | Reported frequency | PZA susceptibility profile | % |
|---|---|---|---|
| Promoter (A-11G) | 1 | Resistant | 0.5 |
| D49N | 1 | Resistant | 0.5 |
| D8E | 2 | Resistant | 1.0 |
| F81S | 2 | Susceptible | 1.0 |
| H51R | 10 | Resistant | 5.2 |
| H57L | 1 | Resistant | 0.5 |
| H57R | 1 | Resistant | 0.5 |
| H71R | 2 | Resistant | 1.0 |
| I6S | 2 | Resistant | 1.0 |
| K48T | 9 | Susceptible | 4.7 |
| P62S | 1 | Susceptible | 0.5 |
| Q10P | 2 | Resistant | 1.0 |
| Q10R | 13 | Resistant | 6.7 |
| Δ375–389 | 1 | Resistant | 0.5 |
| Δ456–466 | 3 | Resistant | 1.6 |
| Wild type | 142 | Susceptible | 73.6 |
Specific mutations are reported along with the strain’s corresponding PZA susceptibility profile according to the Tuberculosis Drug Resistance Mutation Database.
FIG 3Sample distribution by PZA susceptibility profile. Distribution displayed according to the results from Bactec MGIT 960 PZA, pncA sequencing, and classic Wayne test. For stacked numerals, the number of PZA-susceptible isolates is given above the number of PZA-resistant isolates.
Susceptibility to PZA determined by the MODS-Wayne assay for each reading day
| Reading | MODS-Wayne results (no. of isolates susceptible or resistant [% of total]) | |
|---|---|---|
| PZA susceptible | PZA resistant | |
| R1 | 89 (46.1) | 104 (53.9) |
| R2 | 132 (68.4) | 61 (31.6) |
| R3 | 154 (79.8) | 39 (20.2) |
n = 193 isolates. With increasing incubation time, the assay reported an increasing proportion of PZA-susceptible isolates.
Proportion of samples with positive and negative results by MODS-Wayne assay per reading day
| Level of growth in culture ( | No. (%) with result by reading day | |||||
|---|---|---|---|---|---|---|
| R1 | R2 | R3 | ||||
| Positive | Negative | Positive | Negative | Positive | Negative | |
| Microcolonies (14) | 3 (21.4) | 11 (78.6) | 6 (42.9) | 8 (57.1) | 9 (64.3) | 5 (35.7) |
| Low growth (24) | 8 (33.3) | 16 (66.7) | 11 (45.8) | 13 (54.2) | 16 (66.7) | 8 (33.3) |
| Regular growth (58) | 25 (43.1) | 33 (56.9) | 43 (74.1) | 15 (25.9) | 50 (86.2) | 8 (13.8) |
| High growth (97) | 53 (54.6) | 44 (45.4) | 72 (74.2) | 25 (25.8) | 79 (81.4) | 18 (18.6) |
An increase in the number of samples with positive results was observed along the reading days.
Performance of MODS-Wayne assay compared to composite standard
| Reading day | Sensitivity | Specificity | ||
|---|---|---|---|---|
| % (no. of isolates/total no. of isolates) | 95% CI (%) | % (no. of isolates/total no. of isolates) | 95% CI (%) | |
| R1 | 97.6 (40/41) | 87.1–99.9 | 57.9 (88/152) | 49.6–65.9 |
| R2 | 97.6 (40/41) | 87.1–99.9 | 86.2 (131/152) | 79.7–91.2 |
| R3 | 92.7 (38/41) | 80.1–98.5 | 99.3 (151/152) | 96.4–100 |
Each diagnostic value was calculated with 95% CI.